-
Fertility preservation in pediatric solid tumors: A report from the Children's Oncology Group Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-26 Kari Bjornard, Allison Close, Karen Burns, Josuah Chavez, Eric J. Chow, Lillian R. Meacham
Treatment for childhood solid tumors may lead to an increased risk for gonadal dysfunction/infertility. Discussion of risk should occur at diagnosis, any changes in therapy, and during survivorship. Gonadotoxic therapies were abstracted from 32 Children's Oncology Group (COG) phase III, frontline solid tumor protocols, in use from 2000 to 2022. Risk for gonadal dysfunction/infertility was assessed
-
Registration, incidence patterns, and survival trends of central nervous system tumors among children in Germany 1980–2019: An analysis of 40 years based on data from the German Childhood Cancer Registry Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-26 Maike Wellbrock, Mathias Voigt, Cecile Ronckers, Desiree Grabow, Claudia Spix, Friederike Erdmann
Tumors of the central nervous system (CNS) are the second most common type of pediatric cancer in Germany. We aimed to describe registration practice, incidence, and survival patterns for childhood CNS tumors in Germany for the past 40 years.
-
Novel mutation in KIF23 causing congenital dyserythropoietic anemia type III in patients who underwent allogeneic hematopoietic stem cell transplantation Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-25 Tomoko Fujikawa, Suguru Uemura, Daiichiro Hasegawa, Naoya Morisada, Sayaka Nakamura, Aiko Kozaki, Atsuro Saito, Kenji Kishimoto, Toshiaki Ishida, Takeshi Mori, Kimikazu Yakushijin, Yoshio Katayama, Daiki Yamashita, Manabu Wakamatsu, Motoharu Hamada, Hideki Muramatsu, Yoshiyuki Takahashi, Yoshiyuki Kosaka
-
Congenital dyserythropoietic anemia type IV with KLF1 E325K mutation: A new case with dysmorphic male genitalia Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-25 Gita V. Massey, Alden Chesney, Manisha Gadgeel, Yaddanapudi Ravindranath
-
Secondary amenorrhea in a β‐thalassemia major patient treated with thalidomide Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-25 Yang Yu, Kun Yang
-
Philadelphia chromosome‐like B‐acute lymphoblastic leukemia and disseminated juvenile xanthogranulomatosis with shared KRAS mutation Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-25 Jinjun Cheng, Nikolaos Svoronos, Miao Pan, Shelby Smith, Anant Vatsayan, David Jacobsohn, Birte Wistinghausen
-
Low‐dose cytarabine and hypomethylating agents for Down syndrome with acute myeloid leukemia Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-25 Ramya Ramakrishnan, Faryal Munir, Andres Ernesto Quesada, Johann Hitzler, Branko Cuglievan
-
Wiskott–Aldrich syndrome protein expression in female WAS carriers: A flow cytometry study from North India Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-25 Suprit Basu, Rashmi Rikhi, Kanika Arora, Vibhu Joshi, Saniya Sharma, Amit Rawat, Surjit Singh, Deepti Suri
IntroductionWiskott–Aldrich syndrome (WAS) is a rare X‐linked inborn error of immunity characterized by microthrombocytopenia, infections, eczema, and increased predisposition to develop autoimmunity and malignancy. Flow cytometric assay for determining WAS protein (WASp) is a rapid and cost‐effective tool for detecting patients. However, very few studies described WASp expression in female carriers
-
A call for a randomized trial of prophylactic bisphosphonate for decreasing the incidence of osteonecrosis in patients with acute lymphoblastic leukemia Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-23 Bruce Bostrom
CONFLICT OF INTEREST STATEMENT The author declares no conflict of interest.
-
A phase 1/2 study of pepinemab in children, adolescents, or young adults with recurrent or refractory solid tumors: A children's oncology group consortium report (ADVL1614) Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-23 Emily Greengard, Robin Williams, Branden Moriarity, Xiaowei Liu, Charles G. Minard, Joel M. Reid, Terrence Fisher, Elizabeth Evans, Desa Rae Pastore, Maurice Zauderer, Stephan Voss, Elizabeth Fox, Brenda J Weigel
PurposePepinemab, a humanized IgG4 monoclonal antibody, targets the SEMA4D (CD100) antigen to inhibit binding to its high‐affinity receptors (plexin B1/PLXNB1, plexin B2/PLXNB2) and low‐affinity receptor (CD72). SEMA4D blockade leads to increased cytotoxic T‐cell infiltration, delayed tumor growth, and durable tumor rejection in murine tumor models. Pepinemab was well tolerated and improved T cell
-
In Memoriam: Christophe Bergeron Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-23 Arnauld Verschuur, Kathy Pritchard‐Jones, Hans Merks, Gianni Bisogno, Perrine Marec‐Berrard, Marry M. van den Heuvel‐Eibrink
-
Hemolytic uremic syndrome as a rare complication in a case of Castleman disease Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-23 Alexander D. Hsu, Giselle N. Ricoy, Van Savell, Amy Becker, Ndina Nhlane
-
Thrombin activatable fibrinolysis inhibitor plasma levels and TAFI Thr325Ile genetic polymorphism in a cohort of Egyptian sickle cell disease patients and impact on disease severity Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-23 Mona Hamdy, Iman A. Shaheen, Mohamed Khallaf, Yasmeen M. M. Selim
BackgroundThrombin is a critical protease modulating thrombosis as well as inflammation, which are one of the main pathophysiological mechanisms in sickle vasculopathy, and its levels were reported to be high in sickle cell disease (SCD). The thrombin–thrombomodulin complex activates the TAFI inhibitor of fibrinolysis, which acts by reducing plasmin affinity for its substrate thus hindering fibrinolysis
-
Acute disseminated encephalomyelitis as paraneoplastic syndrome preceding pediatric B acute lymphoblastic leukemia Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-23 Mithra Lakshmi Narasimhan, David B. Wilson, Laura G. Schuettpelz
-
Romiplostim as an early treatment for refractory immune thrombocytopenia in a 2‐month‐old infant Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-23 Yuko Chiba, Keiji Tasaka, Kousaku Matsubara, Makiko Mori, Michiko Muraoka, Takayuki Hamabata, Seishiro Nodomi, Kenji Waki
-
Intraoperative radiation therapy for pediatric sarcomas and other solid tumors Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-23 Brianna Conte, Dana L. Casey, Kathryn R. Tringale, Michael P. LaQuaglia, J. Ted Gerstle, Leonard Wexler, Michael V. Ortiz, Suzanne L. Wolden
PurposeTo evaluate local failure (LF) and toxicity after intraoperative radiation therapy (IORT) in pediatric solid tumors (ST).MethodsA single‐institution retrospective study of 96 pediatric patients (108 applications) with ST treated from 1995 to 2022 with IORT. LF was calculated via cumulative incidence function and overall survival (OS) by Kaplan–Meier method, both from the day of surgery.ResultsMedian
-
Palbociclib and chemotherapy followed by blinatumomab consolidation to CAR‐T cell therapy in KMT2A‐rearranged, therapy‐related acute lymphoblastic leukemia Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-22 Sanila Sarkar, Emily Rav, Lea Stitzlein, Amber Gibson, David McCall, Cesar Nunez, Michael Roth, Dristhi Ragoonanan, Jeremy Connors, Cynthia E. Herzog, Branko Cuglievan, Miriam B. Garcia
-
-
Brochure intervention to manage bothersome taste changes in pediatric patients receiving cancer therapy Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-22 Hadeel Hassan, Seye Oloyede, Gillian Villanueva, Serena Zahra, Zakia Joseph‐Frederick, Gloria Green, Tal Schechter, Sue Zupanec, L. Lee Dupuis, Lillian Sung
BackgroundPrimary objective was to determine if a patient informational brochure describing potentially useful strategies could help manage specific taste changes. Secondary objective was to describe the specific strategies used and whether the strategies were perceived as being helpful.ProcedureThis single‐center study included pediatric patients with cancer or hematopoietic cell transplant recipients
-
Palliative care and suicidality: Complicated conversations at two ends of the spectrum Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-21 Maryland Pao, Lisa Horowitz
Lucas and colleagues1 highlight an important and challenging clinical scenario when healthcare providers identify adolescents and young adults (AYA) who find themselves confronting suicidal thoughts in the face of difficult-to-tolerate treatments for a life-limiting illness. As medical technology and therapeutics advance to prolong life, these thorny medically complex clinical situations intertwined
-
The relationship between cumulative risk and health‐related quality of life in youth with sickle cell disease: Moderating effects of secondary control engagement coping Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-16 Elise M. Belkin, Natalie Koskela‐Staples, Elise Turner, L. Vandy Black, David A. Fedele
BackgroundYouth with sickle cell disease (SCD) often experience low health‐related quality of life (HRQOL). Engagement in resilience‐promoting processes, such as secondary control engagement (SCE) coping, or adapting to stressors, may be linked to contextual risk factors (e.g., poverty status). This study aims to illuminate relationships between a cumulative risk index (CRI), SCE coping, and HRQOL
-
Enoxaparin thromboprophylaxis in hospitalized obese pediatric patients Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-15 Juwon Yim, Afrin Jahan, Nikolay Braykov, Nina D. Murphy, Gary M. Woods
BackgroundEnoxaparin is an anticoagulant used for pharmacologic thromboprophylaxis in pediatrics. Enoxaparin pharmacokinetics can be altered in the setting of obesity. Optimal enoxaparin dosing for thromboprophylaxis in children with obesity remains unclear.ProcedureA retrospective review was conducted of pediatric patients who weighed ≥60 kg with BMI ≥ 95th percentile, received enoxaparin for thromboprophylaxis
-
Sequelae and post‐thrombotic syndrome after venous thromboembolism in acute lymphoblastic leukemia survivors treated on the NOPHO ALL2008 protocol Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-14 Merete Dam, Line Stensig Lynggaard, Ólafur G. Jónsson, Sonata Saulyte Trakymiene, Katrin Palk, Kirsten Jarvis, Liv Andrés‐Jensen, Ruta Tuckuviene, Birgitte Klug Albertsen
The treatment of acute lymphoblastic leukemia (ALL) is frequently complicated by toxicity, including venous thromboembolism (VTE) affecting roughly 8% of patients. VTE can lead to post‐thrombotic syndrome (PTS), a group of signs and symptoms developed as a complication to deep venous thrombosis (DVT), imposing risk of permanent disability and reduced quality of life (QoL). PTS prevalence ranges from
-
Comment on: Sarcopenia in long‐term survivors of cancer in childhood and adolescence: A cross‐sectional study of calf muscle mass by peripheral quantitative computed tomography with an examination of the muscle‐bone unit Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-13 Ahmad J. Abdulsalam, Murat Kara, Levent Özçakar
-
Description of a national, multi-center registry of patients with sickle cell disease and SARS-CoV-2 infection: Data from the Pediatric COVID-19 United States Registry Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-12 Aleksandra S. Dain, Caroline Diorio, Brian T. Fisher, Jane S. Hankins, Char M. Witmer, Mickael Boustany, Madeline Burton, Jose Ferrolino, Salma Sadaf, Hailey S. Ross, Gabriela Maron
Children with sickle cell disease (SCD) are at risk of complications from viral infections, including SARS-CoV-2. We present the clinical characteristics and outcomes of pediatric patients with SCD from the Pediatric COVID-19 United States Registry who developed acute COVID-19 due to SARS-CoV-2 infection (n = 259) or multisystem inflammatory syndrome in children (MIS-C; n = 4). Nearly half of hospitalized
-
Targeting BCL11A through gene therapy in sickle cell disease: Will one size fit all or most? Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-12 Abdulrahman Alsultan
-
Social impairment in survivors of pediatric brain tumors via reduced social attention and emotion‐specific facial expression recognition Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-12 Peter M. Fantozzi, Ashley Anil, Sean McHugh, Alannah R. Srsich, Manali Zope, Julia Parish‐Morris, Robert T. Schultz, John Herrington, Matthew C. Hocking
Background/objectivesSurvivors of pediatric brain tumors (SPBT) experience significant social challenges, including fewer friends and greater isolation than peers. Difficulties in face processing and visual social attention have been implicated in these outcomes. This study evaluated facial expression recognition (FER), social attention, and their associations with social impairments in SPBT.MethodsSPBT
-
Feasibility study of micronutrient status and body mass index of newly diagnosed pediatric oncology patients: Research commentary Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-11 Paul C. Rogers, Jeffrey Cheng, Alecia Lim, James E. Potts
We conducted a feasibility study to evaluate micronutrients and body mass index (BMI). Fat soluble vitamins A, D, E and trace elements copper (Cu), selenium (Se), and zinc (Zn) levels were evaluated. Weight, height, BMI, and Z‐scores were recorded. Side effects or specific adverse events were documented. No patient had a Z‐score for height, weight, or BMI of less than 2 SD or greater than 2 SD. Ninety
-
Heterozygous TCF3‐related disease presenting as X‐linked agammaglobulinemia mimicry in a male toddler with B‐cell aplasia, agammaglobulinemia, and severe neutropenia Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-11 Laura M. Bou‐Maroun, Kelly J. Walkovich, Lauren Frazier, Mark Hannibal, Thomas F. Michniacki
-
Primary myeloid sarcoma in an infant with an NRAS mutation Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-11 Aarti Kamat, Valerie Opipari, Clayton Habiger, Rama Jasty, Rajen Mody, Laura Sedig
-
Pediatric splenic infarction: Assessment of associated clinical conditions and outcome Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-11 Evgeny Grishin, Michalle Soudack, Sarina Levy‐Mendelovich, Yael Bezalel, Aharon Lubetsky, Omri Cohen, Tami Brutman‐Barazani, Orly Efros, Gili Kenet, Assaf A. Barg
Pediatric splenic infarction (SI) is rare yet clinically significant. Publications regarding this complication are mostly limited to case reports. This is a retrospective study examining SI etiology, clinical presentation, management, and outcomes among children. Twenty‐two patients (median age: 7.9 years) were included, mostly with pre‐existing hematological diseases. Splenomegaly (72%), thrombocytopenia
-
Prevalence of Duffy null and its impact on hydroxyurea in young children with sickle cell disease in the United States Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-11 Fathia Oladipupo, Joseph Stanek, Joseph Walden, Jennifer Young, Melissa J. Rose, Kathleen Nicol, Anthony Villella, Susan Creary
Consistent with studies showing a high prevalence of the Duffy null phenotype among healthy Black Americans, this retrospective study found that Duffy null was present in >75% of a young and contemporary cohort of children with sickle cell disease (SCD) in the United States. Despite the potential for this phenotype to impact absolute neutrophil counts, hydroxyurea (HU) dosing, and outcomes, it was
-
Adequate menstrual suppression in adolescents with inherited bleeding disorders often requires multiple treatment changes: Retrospective cohort study of a multidisciplinary clinic Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-11 Megan C. Brown, Kelly Tickle, Kalinda Woods, Robert F. Sidonio
Heavy menstrual bleeding (HMB) is often the presenting symptom for females with inherited bleeding disorders (IBD). Multidisciplinary clinics leverage the expertise of hematologists and women's health specialists. This study characterizes the complexity of HMB management for adolescents with IBDs from a large multidisciplinary clinic. Adolescents often required multiple different menstrual suppression
-
Single centre experience of the use of emicizumab in previously untreated and minimally treated patients under 18 months of age Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-11 Eman Hassan, Jayashree Motwani
Emicizumab has revolutionised haemophilia A treatment landscape and significantly reduced treatment burden, particularly in the paediatric population. We conducted a retrospective study, focused on infants aged ≤18 months with severe haemophilia A. The study included 16 patients, with a median age of 8.2 months and median treatment duration of 61.6 weeks. Before commencing emicizumab, six patients
-
Real-world experience of direct oral anticoagulant use in a single pediatric center Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-06 Gianna G. Valenti, Cynthia Sabo, Michelle Hyde, Madhvi Rajpurkar
Pediatric venous thromboembolism has increased by 130%–200%, specifically in hospitalized children, and direct oral anticoagulants (DOACs) offer several therapeutic advantages.
-
How we use angiopoietin-2 in the diagnosis and management of vascular anomalies Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-04 Elissa R. Engel, Timothy D. Le Cras, Kiersten W. Ricci
The diagnosis of vascular anomalies remains challenging due to significant clinical heterogeneity and uncertain etiology. Evaluation using biopsy and/or genetic testing for somatic variants is invasive, expensive, and prone to sampling error. There is great need for noninvasive and easily measured blood laboratory biomarkers that can aid not only in diagnosis, but also management of treatments for
-
-
Efficacy and safety of azacitidine in pediatric patients with newly diagnosed advanced myelodysplastic syndromes before hematopoietic stem cell transplantation in the AZA-JMML-001 trial Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-03 Franco Locatelli, Karin Belander Strålin, Irene Schmid, Julián Sevilla, Owen P. Smith, Marry M. van den Heuvel-Eibrink, Marco Zecca, Christian M. Zwaan, Allison Gaudy, Meera Patturajan, Jennifer Poon, Mathew Simcock, Charlotte M. Niemeyer
Here we report efficacy, pharmacokinetics, and safety data obtained in treatment-naive, pediatric patients with newly diagnosed advanced MDS receiving azacitidine in the AZA-JMML-001 study. The primary endpoint was response rate (proportion of patients with complete response [CR], partial response [PR], or marrow CR, sustained for ≥4 weeks). Of the 10 patients enrolled, one had an unconfirmed marrow
-
Use of modern three-dimensional imaging models to guide surgical planning for local control of pediatric extracranial solid tumors Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-02 Nikhil R. Shah, William J. Weadock, Keyonna M. Williams, Rebecca Moreci, Tammy Stoll, Aparna Joshi, Robin Petroze, Erika A. Newman
In complex pediatric surgical oncology, surgical planning is contingent upon data gathered from preoperative imaging. Three-dimensional (3D) modeling and printing has been shown to be beneficial for adult presurgical planning, though pediatric literature is less robust. The study reviews our institutional experience with the use of 3D image segmentation and printed models in approaching resection of
-
Hypofractionated re-irradiation for diffuse intrinsic pontine glioma Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-02 Nikhil P. Mankuzhy, Kathryn R. Tringale, Ira J. Dunkel, Sameer Farouk Sait, Mark M. Souweidane, Yasmin Khakoo, Matthias A. Karajannis, Suzanne Wolden
Re-irradiation (reRT) increases survival in locally recurrent diffuse intrinsic pontine glioma (DIPG). There is no standard dose and fractionation for reRT, but conventional fractionation (CF) is typically used. We report our institutional experience of reRT for DIPG, which includes hypofractionation (HF).
-
Phantosmia during proton radiation and differences in frequency of phantosmia rates based on proton craniospinal irradiation technique for pediatric brain tumor patients Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-29 Myrsini Ioakeim-Ioannidou, Juliane Daartz, Parsa Erfani, Tobias Urell, Arthur Lalonde, Julia Berv, Shannon Leahy, Barbara Fullerton, Rachel Bolton, Torunn Yock, Nancy Tarbell, Beow Yeap, Shannon M MacDonald
Unusual olfactory perception, often referred to as “phantosmia” or “cacosmia” has been reported during brain radiotherapy (RT), but is infrequent and does not typically interfere with the ability to deliver treatment. We seek to determine the rate of phantosmia for patients treated with proton craniospinal irradiation (CSI) and identify any potential clinical or treatment-related associations.
-
The ASPHO 2024 Distinguished Career Award goes to Dr. David A. Williams Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-29 Akiko Shimamura
CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest.
-
Primary testicular T lymphoblastic lymphoma in a child: Case report from a regional cancer center Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-29 Sathya Murugasamy, Arun Kumar, Hemavathi Narayan, Lingegowda Appaji, Nuthan Kumar, Prakruthi S. Kaushik, Mohana Reddy, Nikila Ravichandran, Thirumala Rupakumar, Meena Haldorai, Avinash Thumallapalli, Bangegadde S. Aruna Kumari
-
Adenoid cystic carcinoma of the parotid and submandibular glands in children and young adults: A population-based study Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-28 Alisa L. Phillips, Cai Li, Jia Liang, Anthony Sheyn, Jeffrey C. Rastatter, Daniel C. Chelius, Daniel Orbach, Celine Richard
This study aims to analyze the behavior and treatment of adenoid cystic carcinoma (AdCC) in the pediatric and young adult population and to identify factors affecting overall survival (OS).
-
Authors’ reply: Intravenous iron for pediatric critically ill children Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-27 Laura Butragueño‐Laiseca, Sara de la Mata Navazo, Amelia Caridad Sánchez Galindo, María José Santiago Lozano
-
you leave a hole Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-26 Erica C. Kaye
CONFLICT OF INTEREST STATEMENT The author declares no conflicts of interest.
-
Absolute neutrophil count clinical trial eligibility criteria for pediatric oncology phase I and phase I/II trials by sponsorship Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-26 Jenny Ruiz, Rebecca K. Kelly, Richard Aplenc, Theodore W. Laetsch, Alix E. Seif
Normal absolute neutrophil count (ANC) variations, as seen with Duffy-null associated neutrophil count (DANC), are not accounted for in trial eligibility, which may contribute to racial enrollment disparities. We describe ANC eligibility for pediatric oncology phase I/II clinical trials according to primary sponsorship from 2010 to 2023 using ClinicalTrials.gov. Out of 438 trials, 20% were industry-sponsored
-
Hematopoietic stem cell transplantation in two sisters with bone marrow failure associated with POLE gene variants Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-26 Kentaro Fujimori, Norihito Ikenobe, Yoshihiro Gocho, Toru Uchiyama, Takao Deguchi, Hirotoshi Sakaguchi, Daisuke Tomizawa, Ichiro Takeuchi, Hirotaka Shimizu, Katsuhiro Arai, Akira Ishiguro, Kimikazu Matsumoto, Akihiro Iguchi
-
-
Oh rats! Intracellular rod‐like inclusions in an adolescent with Shwachman–Diamond syndrome Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-23 Jonathan Mayhew, Harrison Luttrell, Kathryn Barros, Lindsay Blazin, Cydney Nichols, Nidhi Avashia‐Khemka, John‐Paul Lavik, Ryan F. Relich, Deryll Skinner, Jiehao Zhou, Amanda Saraf, Alka Khaitan
-
Pancreatic iron in pediatric transfusion-dependent beta-thalassemia patients: A longitudinal MRI study Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-22 Antonella Meloni, Laura Pistoia, Maria Caterina Putti, Filomena Longo, Elisabetta Corigliano, Paolo Ricchi, Vincenza Rossi, Tommaso Casini, Riccardo Righi, Stefania Renne, Giuseppe Peritore, Luigi Barbuto, Vincenzo Positano, Filippo Cademartiri
In pediatric transfusion-dependent thalassemia (TDT) patients, we evaluated the prevalence, pattern, and clinical associations of pancreatic siderosis and the changes in pancreatic iron levels and their association with baseline and changes in total body iron balance.
-
Delayed serum sickness reaction after initial hypersensitivity reaction to calaspargase during treatment for B‐cell acute lymphoblastic leukemia Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-21 Kelsey Gay, Gayle Smink, Kevin Mulieri, Smita Dandekar
-
The evidence is mounting: Insurance coverage disruptions lead to worse outcomes among children diagnosed with cancer Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-20 Philip J. Lupo, Christina L. Magyar
CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest.
-
Assessing coagulopathy and endothelial dysfunction in pediatric venous malformation: A thromboelastometry and syndecan-1 study Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-18 Francisco Nava y Hurtado, Elena Monzon Manzano, Vanesa Viana-Huete, Paloma Triana Junco, Maria Teresa Alvarez-Roman, Elena G. Arias-Salgado, Nora Butta, Juan Carlos Lopez Gutierrez
The occurrence of unpredictable pain crises are the principal determinant of the quality of life for patients with venous malformations (VM). A definite coagulation phenomenon, characterized by an increase in D-dimer levels and the presence of phleboliths within the malformation, has been previously reported. By applying Virchow's triad and evaluating intralesional samples, our objective is to delineate
-
Excellent response to treatment with hydroxychloroquine in pediatric patients with SLE-related immune thrombocytopenia Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-13 Dafna Brik-Simon, Orly Efros, Yoel Levinsky, Gil Amarilyo, Irit Tirosh, Sarina Levy-Mendelovich, Orna Steinberg-Shemer, Shai Izraeli, Joanne Yacobovich, Oded Gilad
Pediatric immune thrombocytopenia (ITP) may precede systemic autoimmune disorders. In adolescent patients with ITP, routine screening for systemic lupus erythematosus (SLE) may be performed by testing for antinuclear antibody (ANA) titer. Hydroxychloroquine (HCQ) is a safe and effective immunomodulatory drug in patients with SLE but rarely used in ITP. We analyzed the platelet count response and safety
-
Electrocardiographic abnormalities in patients with sickle cell disease: A systematic review and meta-analysis Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-13 Erfan Taherifard, Hamed Movahed, Ehsan Taherifard, Alireza Sadeghi, Niloofar Dehdari Ebrahimi, Alireza Ahmadkhani, Fatemeh Kheshti, Hossein Movahed
Previous studies have documented that electrocardiography (ECG) can reveal a range of abnormalities, offering valuable insights into the cardiac evaluation of patients with sickle cell disease (SCD). The objective of this study is to assess the patterns of ECG abnormalities observed in these patients with SCD, and to determine their prevalence.
-
Pain screening in youth with sickle cell disease: A quality improvement study Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-13 Dennis C. Vroom, Samuel N. Rodgers-Melnick, Tracie Brown, Amma Owusu-Ansah, Jeffery A. Dusek
Youth with sickle cell disease (SCD) face several challenges as they age, including increased pain frequency, duration, and interference. The purpose of this study was to (i) determine the feasibility of routine pain screening; (ii) identify and describe various clinical pain presentations; and (iii) understand preferences/resources related to engaging in integrative health and medicine (IHM) modalities
-
Survivors of infant atypical teratoid/rhabdoid tumors present with severely impaired cognitive functions especially for fluid intelligence and visual processing: data from the German brain tumor studies Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-11 Thomas Traunwieser, Elena Loos, Holger Ottensmeier, Katharina Gastberger, Karolina Nemes, Martin Mynarek, Brigitte Bison, Daniela Kandels, Petra Neumayer, Anne Neumann-Holbeck, Peggy Lüttich, Katja Baust, Kristin Faulstich-Ritter, Rainer John, Andrea Kreisch, Judyta Landmann, Eva Manteufel, Alexandra Nest, Jenny Prüfe, Lisa Schubert, Walther Stamm, Beate Timmermann, Joachim Gerss, Stefan Rutkowski
The contribution of tumor type, multimodal treatment, and other patient-related factors upon long-term cognitive sequelae in infant brain tumor survivors remains undefined. We add our retrospective analysis of neuropsychological and quality of survival (QoS) outcome data of survivors of atypical teratoid/rhabdoid tumors (ATRT) and extracranial malignant rhabdoid tumors of the soft tissues (eMRT) and
-
Shifting perspectives and transformative change: Parent perspectives of an active music engagement intervention for themselves and their child with cancer Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-09 Kristin Stegenga, Amanda K. Henley, Elizabeth Harman, Sheri L. Robb
Children with cancer (ages 3–8 years) and their parents experience significant, interrelated distress associated with cancer treatment. Active music engagement (AME) uses music-based play and shared music-making to mitigate this distress. To advance our understanding about how AME works and its essential features, we interviewed parents who received the AME intervention as part of a multi-site mechanistic
-
Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment (HABIT) efficacy trial: Community health worker support may increase hydroxyurea adherence of youth with sickle cell disease Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-06 Nancy S. Green, Deepa Manwani, Banu Aygun, Abena Appiah-Kubi, Kim Smith-Whitley, Yina Castillo, Lucy Soriano, Haomiao Jia, Arlene M. Smaldone
Despite disease-modifying effects of hydroxyurea on sickle cell disease (SCD), poor adherence among affected youth commonly impedes treatment impact. Following our prior feasibility trial, the “Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment (HABIT)” multi-site randomized controlled efficacy trial aimed to increase hydroxyurea adherence for youth with SCD ages 10–18 years. Impaired